Phathom Pharmaceuticals Inc (PHAT) Earning Prediction
Phathom Pharmaceuticals Inc (PHAT) is set to release its earnings performance on 03/12 07:00:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 57.42M and an earnings per share (EPS) of -0.20 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
PHAT Transcript
The earnings call indicates strong financial discipline with reduced expenses and debt, a solid cash position, and consistent gross margins. The sales force realignment is showing positive momentum, and regulatory exclusivity is extended. Although Q1 is expected to be weak, the full-year guidance is optimistic. The Q&A section reflects positive sentiment towards the company's strategy, despite some uncertainties. The absence of a market cap suggests considering this as a small-cap reaction, leading to a positive stock price movement prediction.
The earnings call summary and Q&A session indicate positive sentiment. The company has strong revenue guidance for 2025, plans for profitability by 2026, and reduced cash usage. The Q&A revealed management's confidence in overcoming challenges, such as prescription growth and advertising cuts. The strategic focus on gastroenterology practices and the expected inflection point in sales suggest positive momentum. While there are some uncertainties, the overall outlook is optimistic, leading to a positive sentiment rating.
The earnings call summary presents mixed signals: strong gross margins and a strategic focus on GI market growth are positives, while increased expenses and unclear revenue guidance pose concerns. The Q&A reveals management's cautious optimism but lack of precise timelines for revenue acceleration and cost reductions, which may create uncertainty. The company's focus on the U.S. market and cost-cutting measures are prudent, yet the potential delay in revenue growth and increased expenses temper positive sentiment, leading to a neutral stock price prediction.
Despite potential growth avenues like the VOQUEZNA launch and cost-saving initiatives, Phathom faces financial instability with significant losses and competitive pressures. The Q&A revealed uncertainties in FDA interactions and unclear management responses, adding to investor concerns. While there is a focus on profitability by 2026, the lack of immediate positive catalysts and the financial performance suggest a negative sentiment, likely leading to a stock price decline in the short term.
PHAT Slides
Phathom Q4 2025 slides: 217% revenue growth, profitability in sightPhathom Pharmaceuticals Q3 2025 slides: Revenue up 25% as expenses drop 43%Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beatPhathom Q1 2025 slides: VOQUEZNA adoption rises as company targets 2026 profitabilityPHAT Report
Frequently Asked Questions
What is the Phathom Pharmaceuticals Inc {quarter} Earnings Release Date and Time?
Phathom Pharmaceuticals Inc (PHAT) is scheduled to release its {quarter} earnings report on Mar 12, 2026, Pre-Market (approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Phathom Pharmaceuticals Inc {quarter} Revenue and EPS?
Analysts' consensus predicts 57.42M in revenue and an EPS of -0.20 for Phathom Pharmaceuticals Inc's {quarter}.
What Does Intellectia's AI Predict for Phathom Pharmaceuticals Inc {quarter} Earnings?
Intellectia's exclusive AI algorithms forecast a {conclusion} for Phathom Pharmaceuticals Inc's {quarter} earnings, with a prediction date of Mar 12, 2026. Phathom Pharmaceuticals Inc {summary}
How Can I Use This Earnings Prediction to Trade PHAT Stock?
Leverage Intellectia's AI forecast to position trades ahead of the Mar 12, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Phathom Pharmaceuticals Inc {quarter}?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company's earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They're updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
